Nationwide Fund Advisors boosted its position in Jounce Therapeutics Inc (NASDAQ:JNCE) by 71.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 20,523 shares of the company’s stock after buying an additional 8,577 shares during the quarter. Nationwide Fund Advisors owned approximately 0.06% of Jounce Therapeutics worth $320,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently added to or reduced their stakes in the company. Teachers Advisors LLC boosted its holdings in shares of Jounce Therapeutics by 26.4% in the second quarter. Teachers Advisors LLC now owns 11,231 shares of the company’s stock worth $158,000 after acquiring an additional 2,347 shares during the period. Ark Investment Management LLC boosted its holdings in shares of Jounce Therapeutics by 558.9% in the second quarter. Ark Investment Management LLC now owns 11,932 shares of the company’s stock worth $167,000 after acquiring an additional 10,121 shares during the period. Alliancebernstein L.P. bought a new position in shares of Jounce Therapeutics in the second quarter worth $177,000. Teachers Retirement System of The State of Kentucky boosted its holdings in shares of Jounce Therapeutics by 180.0% in the second quarter. Teachers Retirement System of The State of Kentucky now owns 12,600 shares of the company’s stock worth $177,000 after acquiring an additional 8,100 shares during the period. Finally, Swiss National Bank bought a new position in shares of Jounce Therapeutics in the second quarter worth $188,000. 47.51% of the stock is owned by institutional investors and hedge funds.
Shares of Jounce Therapeutics Inc (NASDAQ:JNCE) opened at $15.01 on Thursday. Jounce Therapeutics Inc has a 52 week low of $11.05 and a 52 week high of $29.29. The stock has a market capitalization of $460.47 and a PE ratio of -88.29.
Jounce Therapeutics (NASDAQ:JNCE) last issued its quarterly earnings results on Monday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.12. Jounce Therapeutics had a negative return on equity of 1.39% and a negative net margin of 2.03%. The firm had revenue of $18.10 million during the quarter, compared to analyst estimates of $20.00 million. The business’s revenue for the quarter was up 7.1% on a year-over-year basis. equities analysts predict that Jounce Therapeutics Inc will post -0.86 earnings per share for the current fiscal year.
A number of equities analysts have recently commented on the company. JPMorgan Chase & Co. set a $28.00 price target on Jounce Therapeutics and gave the stock a “buy” rating in a report on Monday, November 13th. Robert W. Baird reissued an “outperform” rating and set a $30.00 price objective on shares of Jounce Therapeutics in a research note on Monday, September 18th. Finally, Zacks Investment Research raised Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research note on Wednesday, January 3rd. Five analysts have rated the stock with a buy rating, Jounce Therapeutics has a consensus rating of “Buy” and an average price target of $24.00.
TRADEMARK VIOLATION NOTICE: “Nationwide Fund Advisors Has $320,000 Stake in Jounce Therapeutics Inc (NASDAQ:JNCE)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/01/11/jounce-therapeutics-inc-jnce-shares-bought-by-nationwide-fund-advisors.html.
About Jounce Therapeutics
Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.